ADPT

SEC source: 0001209191-21-021548 · doc4.xml · nonDerivative · entry 3

BENZENO SHARON · CIK 0001780854 · Chief Business Development Off

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,894

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020.

F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $41.51 to 42.31, inclusive.

SEC source: 0001209191-21-021548 · doc4.xml · nonDerivative · entry 2

BENZENO SHARON · CIK 0001780854 · Chief Business Development Off

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,908

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020.

F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $40.51 to 41.50, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001209191-21-021548 · doc4.xml · nonDerivative · entry 1

BENZENO SHARON · CIK 0001780854 · Chief Business Development Off

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,248

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020.

SEC source: 0000902664-21-001835 · ownership.xml · nonDerivative · entry 9

GOEL DAVID E. · CIK 0001548144 · Director · See Remarks

Matrix Capital Management Company, LP · CIK 0001410830 · Director · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 12,309,090

F9 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $42.01 to $42.685, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F10 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F11 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

SEC source: 0000902664-21-001835 · ownership.xml · nonDerivative · entry 8

GOEL DAVID E. · CIK 0001548144 · Director · See Remarks

Matrix Capital Management Company, LP · CIK 0001410830 · Director · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 12,339,358

F8 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $41 to $42, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F10 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F11 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

SEC source: 0001209191-21-020302 · doc4.xml · derivative · entry 3

Cohen Chad M · CIK 0001524314 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,000

Underlying: Common Stock · 10,000 shares

Expires 2025-08-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020.

F3 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001209191-21-020302 · doc4.xml · nonDerivative · entry 2

Cohen Chad M · CIK 0001524314 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,604

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020.

F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $41.90 to 42.825, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001209191-21-020302 · doc4.xml · nonDerivative · entry 1

Cohen Chad M · CIK 0001524314 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,604

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020.

SEC source: 0000902664-21-001835 · ownership.xml · nonDerivative · entry 7

GOEL DAVID E. · CIK 0001548144 · Director · See Remarks

Matrix Capital Management Company, LP · CIK 0001410830 · Director · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 12,365,090

F7 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $41.005 to $41.66, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F10 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F11 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

SEC source: 0000902664-21-001835 · ownership.xml · nonDerivative · entry 6

GOEL DAVID E. · CIK 0001548144 · Director · See Remarks

Matrix Capital Management Company, LP · CIK 0001410830 · Director · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 12,399,392

F6 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $40 to $41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F10 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F11 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

SEC source: 0001209191-21-019621 · doc4.xml · derivative · entry 4

Cohen Chad M · CIK 0001524314 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,000

Underlying: Common Stock · 10,000 shares

Expires 2025-08-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020.

F4 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001209191-21-019621 · doc4.xml · nonDerivative · entry 3

Cohen Chad M · CIK 0001524314 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,064

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020.

F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $40.57 to 41.09, inclusive.

SEC source: 0001209191-21-019621 · doc4.xml · nonDerivative · entry 2

Cohen Chad M · CIK 0001524314 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,954

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020.

F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $39.50 to 40.49, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001209191-21-019621 · doc4.xml · nonDerivative · entry 1

Cohen Chad M · CIK 0001524314 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,064

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020.

SEC source: 0000902664-21-001835 · ownership.xml · nonDerivative · entry 5

GOEL DAVID E. · CIK 0001548144 · Director · See Remarks

Matrix Capital Management Company, LP · CIK 0001410830 · Director · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 12,615,090

F5 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $41.495, to $41.945, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F10 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F11 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

SEC source: 0000902664-21-001835 · ownership.xml · nonDerivative · entry 4

GOEL DAVID E. · CIK 0001548144 · Director · See Remarks

Matrix Capital Management Company, LP · CIK 0001410830 · Director · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 12,701,001

F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $40.49 to $41.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F10 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F11 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

SEC source: 0000902664-21-001835 · ownership.xml · nonDerivative · entry 3

GOEL DAVID E. · CIK 0001548144 · Director · See Remarks

Matrix Capital Management Company, LP · CIK 0001410830 · Director · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 12,772,195

F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $39.845 to $40.465, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F10 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F11 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

SEC source: 0000902664-21-001835 · ownership.xml · nonDerivative · entry 2

GOEL DAVID E. · CIK 0001548144 · Director · See Remarks

Matrix Capital Management Company, LP · CIK 0001410830 · Director · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 12,805,795

F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $38.83 to $39.83, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F10 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F11 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

SEC source: 0000902664-21-001835 · ownership.xml · nonDerivative · entry 1

GOEL DAVID E. · CIK 0001548144 · Director · See Remarks

Matrix Capital Management Company, LP · CIK 0001410830 · Director · See Remarks

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 12,880,795

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $37.8275 to $38.825, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

F10 · ownership.nature: The securities reported herein are held by Matrix Capital Management Master Fund, LP (the "Matrix Fund"). Matrix Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the Managing General Partner of the Investment Manager.

F11 · ownership.nature: The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

SEC source: 0001209191-21-019620 · doc4.xml · derivative · entry 3

HERSHBERG ROBERT · CIK 0001274139 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,000

Underlying: Common Stock · 2,000 shares

Expires 2023-02-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2020.

F2 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001209191-21-019620 · doc4.xml · nonDerivative · entry 2

HERSHBERG ROBERT · CIK 0001274139 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2020.

SEC source: 0001209191-21-019620 · doc4.xml · nonDerivative · entry 1

HERSHBERG ROBERT · CIK 0001274139 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2020.

SEC source: 0001209191-21-019619 · doc4.xml · derivative · entry 3

HERSHBERG ROBERT · CIK 0001274139 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,000

Underlying: Common Stock · 2,000 shares

Expires 2023-02-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2020.

F2 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001209191-21-019619 · doc4.xml · nonDerivative · entry 2

HERSHBERG ROBERT · CIK 0001274139 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,504

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2020.

SEC source: 0001209191-21-019619 · doc4.xml · nonDerivative · entry 1

HERSHBERG ROBERT · CIK 0001274139 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,504

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2020.

SEC source: 0001209191-21-018741 · doc4.xml · derivative · entry 2

ADAMS R MARK · CIK 0001808905 · EVP & Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,511

Underlying: Common Stock · 51,511 shares

Expires 2021-03-04

F1 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on March 4, 2022, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001209191-21-018741 · doc4.xml · nonDerivative · entry 1

ADAMS R MARK · CIK 0001808905 · EVP & Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,604

SEC source: 0001209191-21-018746 · doc4.xml · derivative · entry 2

Palaniappan Jyoti · CIK 0001807021 · SVP, Diagnostics, immunoSEQ Dx

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,894

Underlying: Common Stock · 22,894 shares

Expires 2021-03-04

F1 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on March 4, 2022, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001209191-21-018746 · doc4.xml · nonDerivative · entry 1

Palaniappan Jyoti · CIK 0001807021 · SVP, Diagnostics, immunoSEQ Dx

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,158

SEC source: 0001209191-21-018743 · doc4.xml · derivative · entry 2

Taylor Stacy L · CIK 0001799081 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,341

Underlying: Common Stock · 34,341 shares

Expires 2021-03-04

F1 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on March 4, 2022, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001209191-21-018743 · doc4.xml · nonDerivative · entry 1

Taylor Stacy L · CIK 0001799081 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,036

SEC source: 0001209191-21-018740 · doc4.xml · derivative · entry 2

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 171,703

Underlying: Common Stock · 171,703 shares

Expires 2021-03-04

F1 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on March 4, 2022, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001209191-21-018740 · doc4.xml · nonDerivative · entry 1

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,778,461

SEC source: 0001209191-21-018739 · doc4.xml · derivative · entry 3

LO FRANCIS · CIK 0001780660 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,511

Underlying: Common Stock · 51,511 shares

Expires 2021-03-04

F1 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on March 4, 2022, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001209191-21-018739 · doc4.xml · nonDerivative · entry 1

LO FRANCIS · CIK 0001780660 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,604

SEC source: 0001209191-21-018744 · doc4.xml · derivative · entry 2

RUBINSTEIN JULIE · CIK 0001780664 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 114,469

Underlying: Common Stock · 114,469 shares

Expires 2021-03-04

F1 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on March 4, 2022, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001209191-21-018744 · doc4.xml · nonDerivative · entry 1

RUBINSTEIN JULIE · CIK 0001780664 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,788

SEC source: 0001209191-21-018747 · doc4.xml · derivative · entry 2

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 171,703

Underlying: Common Stock · 171,703 shares

Expires 2021-03-04

F1 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on March 4, 2022, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001209191-21-018747 · doc4.xml · nonDerivative · entry 1

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,360

SEC source: 0001209191-21-018745 · doc4.xml · derivative · entry 2

BALDO LANCE · CIK 0001780773 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,234

Underlying: Common Stock · 57,234 shares

Expires 2021-03-04

F1 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on March 4, 2022, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001209191-21-018745 · doc4.xml · nonDerivative · entry 1

BALDO LANCE · CIK 0001780773 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,894

SEC source: 0001209191-21-018742 · doc4.xml · derivative · entry 2

BENZENO SHARON · CIK 0001780854 · Chief Business Development Off

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,234

Underlying: Common Stock · 57,234 shares

Expires 2021-03-04

F1 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on March 4, 2022, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001209191-21-018742 · doc4.xml · nonDerivative · entry 1

BENZENO SHARON · CIK 0001780854 · Chief Business Development Off

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,894

SEC source: 0001209191-21-018738 · doc4.xml · derivative · entry 2

Cohen Chad M · CIK 0001524314 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,511

Underlying: Common Stock · 51,511 shares

Expires 2021-03-04

F1 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on March 4, 2022, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001209191-21-018738 · doc4.xml · nonDerivative · entry 1

Cohen Chad M · CIK 0001524314 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,604

SEC source: 0001209191-21-018737 · doc4.xml · derivative · entry 2

BOBULSKY SUSAN · CIK 0001820885 · SVP, Diagnostics, clonoSEQ

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,894

Underlying: Common Stock · 22,894 shares

Expires 2021-03-04

F1 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on March 4, 2022, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001209191-21-018737 · doc4.xml · nonDerivative · entry 1

BOBULSKY SUSAN · CIK 0001820885 · SVP, Diagnostics, clonoSEQ

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,158

SEC source: 0001209191-21-017307 · doc4.xml · derivative · entry 5

RUBINSTEIN JULIE · CIK 0001780664 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 225,325

Underlying: Common Stock · 15,000 shares

Expires 2028-02-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020.

F5 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on November 1, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001209191-21-017307 · doc4.xml · nonDerivative · entry 4

RUBINSTEIN JULIE · CIK 0001780664 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020.

F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $58.96 to 59.02, inclusive.

SEC source: 0001209191-21-017307 · doc4.xml · nonDerivative · entry 3

RUBINSTEIN JULIE · CIK 0001780664 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 845

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020.

F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $57.955 to 58.95, inclusive.